Peptides With GLP-1: Stacking Risks and Unknowns
People add MOTS-c, tesamorelin, NAD+ and other compounds to semaglutide or tirzepatide. Learn what the labels say, what nobody has tested, why to tell your prescriber, and how to track each compound.
Last reviewed
The Vital angle
Vital lets you save each GLP-1 medication and peptide on its own and log every dose with the amount, site, symptoms and a severity. You can export your dose history as a PDF that lists each compound by date, so your prescriber can match it to the day a symptom started. Vital is a tracking tool and does not suggest any combination or dose.
Why people take peptides with GLP-1 medications
Many people who use a GLP-1 medication, such as semaglutide or tirzepatide, also take other peptides with GLP-1 treatment. A GLP-1 peptide stack can include MOTS-c, tesamorelin, NAD+, BPC-157 or a second weight-loss compound. The usual goals are to keep muscle, to lower visceral fat, to feel more energy, or to speed recovery.
The evidence for these combinations is very thin. Clinical trials of semaglutide and tirzepatide tested each drug on its own or with standard diabetes medications. They did not test these add-on peptides. This guide explains what the official labels say, what is not known, and how to keep a clear record. It does not recommend any compound, dose, schedule or combination.
What the GLP-1 labels say about other drugs
The FDA labels for GLP-1 medications contain a few facts that matter for any stack. The Zepbound® label is a clear example:
- Tirzepatide slows gastric emptying. That can change how well oral medications and oral supplements are absorbed. The label tells prescribers to monitor oral drugs with a narrow therapeutic range, such as warfarin.
- The label says tirzepatide can make oral hormonal contraceptives less effective after the start and after each dose increase.
- The risk of low blood sugar is higher when tirzepatide is combined with insulin or a sulfonylurea.
- The label does not recommend use with other tirzepatide products or with any other GLP-1 receptor agonist.
Semaglutide labels, such as Wegovy® and Ozempic®, contain similar points about gastric emptying, low blood sugar and use with other GLP-1 drugs. Your prescriber and pharmacist can check your exact label. Side effects often rise after a dose change, as described in side effects after a dose increase.
Two GLP-1 medications at once
Some stacks combine two incretin drugs, for example semaglutide with tirzepatide, or a GLP-1 medication with retatrutide. The labels of approved GLP-1 drugs do not recommend combining them with other GLP-1 receptor agonists. Retatrutide is an investigational drug. It is in clinical trials and is not FDA-approved for any use. Products sold online as retatrutide are not approved drugs.
Combining incretin drugs can increase the gut side effects, the risk of dehydration and the risk of low blood sugar. For background on retatrutide units, see retatrutide dose units and mg conversion. If you want to change medications, see switching semaglutide to tirzepatide and plan the change with your prescriber.
MOTS-c with GLP-1
MOTS-c is a short peptide encoded in mitochondrial DNA. Animal and cell studies link it to muscle and glucose metabolism, which is why people pair it with weight-loss drugs. MOTS-c is not an FDA-approved drug. The FDA bulk-substance page current as of April 22, 2026 lists it in a table of withdrawn compounding nominations. The FDA says it has not identified human exposure data for MOTS-c drug products and notes a possible immunogenicity risk. A July 2026 advisory committee vote in favor of compounding MOTS-c does not bind the FDA and is not an approval.
No published trial has tested MOTS-c with semaglutide or tirzepatide. Because both can affect glucose, the combined effect on blood sugar is unknown. For a comparison with other mitochondrial compounds, see MOTS-c vs SS-31 vs NAD+.
Tesamorelin and tirzepatide
Tesamorelin is different from most compounds in this guide because it is an FDA-approved drug. Egrifta® (tesamorelin) is approved to reduce excess abdominal fat in adults with HIV who have lipodystrophy. It is a growth hormone-releasing hormone analog, so it raises growth hormone and IGF-1.
The tesamorelin label warns that it can cause glucose intolerance and diabetes, and it tells prescribers to check glucose before and during treatment. It also notes fluid retention and the need to watch for diabetic eye disease. Tirzepatide and semaglutide lower glucose. The combined effect of the two drugs on glucose has not been studied in a trial, so a prescriber has to watch the numbers. Use outside the label, and tesamorelin from unregulated sellers, add more unknowns.
NAD+ with semaglutide
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme in every cell. Clinics sell it as an IV infusion or an injection, and stores sell oral precursors. Clinical trials that show a health benefit from these products are not available.
A 2026 retrospective study of IV infusions at a commercial clinic reported gut symptoms, a faster heart rate and chest pressure in many people during NAD+ infusions. Nausea is also a common GLP-1 side effect. When both start in the same week, it is hard to tell which one causes the nausea. No trial has tested NAD+ with semaglutide. For GLP-1 nausea, see GLP-1 nausea relief.
Why to tell your prescriber about every compound
A prescriber can only judge risk with a complete list. Tell them about each peptide, supplement and over-the-counter product, even if it feels awkward. This matters for these reasons:
- Your GLP-1 dose plan depends on your side effects. A side effect from another compound can look like a GLP-1 side effect.
- Some compounds change glucose, so blood sugar checks and diabetes medications can need a change.
- Slower gastric emptying can change how oral products work.
- Before surgery or sedation, the care team needs to know about every drug that affects the stomach.
- Unapproved peptides from unregulated sellers can contain the wrong amount or a different substance.
The FDA reports adverse events, some that needed hospital care, that may be linked to dosing errors with compounded semaglutide. Confirm every draw and every unit conversion with your prescriber or pharmacist. See U-40 vs U-100 syringes for syringe markings.
How to track symptoms per compound
When you take more than one compound, a clear record is the best way to separate their effects. It does not make a stack safer.
- Start or change only one compound at a time, and only with your prescriber's agreement.
- Record each compound, the source, the lot number and the start date.
- Log each dose with the date, time, amount and injection site.
- Log symptoms on the day they start, with a severity, next to the doses of that day.
- Note the date of every dose change for every compound.
- Bring the record to each visit. A dose log for a doctor visit shows one format.
Half-lives differ a lot, so a symptom can come from a dose taken days earlier. See peptide half-life for context.
Urgent warning signs
Get medical care right away for any of these signs:
- Severe stomach pain that does not go away, with or without vomiting. It can be a sign of pancreatitis.
- Pain in the upper right abdomen, fever or yellow skin or eyes.
- Signs of low blood sugar, such as shaking, sweating, confusion or a fast heartbeat.
- Vomiting or diarrhea that stops you from keeping fluids down, or very little urine.
- A hot, red or spreading injection site, or fever.
Get emergency care for swelling of the face, lips, tongue or throat, trouble breathing, fainting or chest pain. The GLP-1 side effects guide lists more signs.
Wegovy®, Ozempic® are trademarks of Novo Nordisk A/S. Zepbound® is a trademark of Eli Lilly and Company. Egrifta® (tesamorelin) is a trademark of Theratechnologies. Vital is independent and not affiliated with these companies.
Things to watch
Practical flags drawn from prescribing information and clinical guidance. Vital surfaces these in the dose log to help you spot them early.
Two incretin drugs at once
Approved GLP-1 labels do not recommend use with other GLP-1 receptor agonists. Combining them can increase gut side effects, dehydration and low blood sugar risk.
Retatrutide
Retatrutide is an investigational drug in clinical trials. It is not FDA-approved, and products sold online under that name are not approved drugs.
MOTS-c and other unapproved peptides
MOTS-c is not an FDA-approved drug, and the FDA has not identified human exposure data for MOTS-c drug products. No trial has tested it with semaglutide or tirzepatide.
Tesamorelin and glucose
The tesamorelin label warns of glucose intolerance and diabetes. The combined effect with a GLP-1 medication on glucose has not been studied in a trial.
Oral products during GLP-1 treatment
GLP-1 medications slow gastric emptying, which can change the absorption of oral drugs, oral contraceptives and oral supplements.
NAD+ infusions
Outcome trials that show a clinical benefit are not available. Infusions can cause gut symptoms that are hard to separate from GLP-1 nausea.
Frequently asked questions
Some people do, but clinical trials of semaglutide and tirzepatide did not test add-on peptides such as MOTS-c, NAD+ or BPC-157. The combined effects are unknown. Ask your prescriber before you add anything.
No published trial has tested that combination. MOTS-c is not an FDA-approved drug, and the FDA has not identified human exposure data for MOTS-c drug products. Both can affect glucose, so the combined effect on blood sugar is unknown.
Tesamorelin (Egrifta) is FDA-approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. Its label warns of glucose intolerance. No trial has studied it with tirzepatide, so a prescriber must decide and monitor glucose.
No trial has tested the combination. NAD+ infusions can cause nausea and other gut symptoms, which overlap with semaglutide side effects. Tell your prescriber before you start, and log symptoms each day.
Approved GLP-1 labels do not recommend use with other GLP-1 receptor agonists. Retatrutide is investigational and not FDA-approved. Talk to your prescriber about any change instead of adding a second drug.
Start or change one compound at a time, only with your prescriber's agreement. Log each dose and each symptom with the date and a severity, so the timeline shows which change came first.
Sources
- Zepbound (tirzepatide) injection: prescribing information · DailyMed, U.S. National Library of Medicine
- Egrifta WR (tesamorelin) for injection: prescribing information · DailyMed, U.S. National Library of Medicine
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks · U.S. Food and Drug Administration
- FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss · U.S. Food and Drug Administration
- Intravenous infusion of NAD+ versus nicotinamide riboside: a retrospective tolerability pilot study in a real-world setting · NIH / PubMed
This page summarizes publicly available information from the sources listed above and is for educational use only. It is not medical advice. Consult a qualified healthcare professional for personal dosing guidance.
Track every shot, every change
Vital logs every GLP-1 injection and peptide dose, then surfaces patterns your scale can't show. Free on iOS and Android.
More from the Library
CJC-1295 Ipamorelin Dosage Chart: Blend Units and the Each vs Total Error
CJC-1295 ipamorelin dosage questions answered with facts: neither compound is FDA-approved, what a 5 mg / 5 mg vial holds, how a blend draw splits into each component, the each vs total math error, and DAC vs no DAC.
GHK-Cu Injection Dosage: What the Evidence Shows and How the Unit Math Works
There is no approved GHK-Cu injection dosage. Learn what the topical and injected evidence shows, where the FDA stands in 2026, how units work for a 50 mg vial, and which side effects need care.
Glow Peptide Blend: What Is in the Vial, Its Status, and the Unit Math
The Glow peptide blend mixes GHK-Cu, BPC-157 and TB-500 in one vial, often sold as 70 mg. Learn what each part is, why no approved dose exists, how Glow differs from KLOW, and how the per-component math works.
How to Read a Peptide Vial Label: mg, Concentration, Lot Number, and Expiry
How to read a peptide vial label step by step: total mg vs mg per mL, blend labels, lot number and expiry, the 28-day rule for opened vials, and what a research use only label means.